Anti-Aging Pharmacology

1st Edition - December 7, 2022
Editor: Vitaly Koltover
Language: English
Paperback ISBN:
9 7 8 - 0 - 1 2 - 8 2 3 6 7 9 - 6
eBook ISBN:
9 7 8 - 0 - 1 2 - 8 2 3 6 8 0 - 2

*Association of American Publishers (AAP) PROSE Award Finalist in Clinical Medicine, 2024*Anti-Aging Pharmacology provides an overview of current research aimed at the pharmacolo… Read more

Purchase options

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Institutional subscription on ScienceDirect

Request a sales quote

*Association of American Publishers (AAP) PROSE Award Finalist in Clinical Medicine, 2024*

Anti-Aging Pharmacology provides an overview of current research aimed at the pharmacological modulation of aging, including a discussion of the growing number of novel drug classes with promising anti-aging potential. The aging process is the main risk factor for all chronic diseases affecting the elderly. With lifespans extending across the globe, these chronic diseases are placing a larger burden on individuals and health care systems. Therefore, slowing down the aging rate could be more effective in delaying aging-associated chronic disorders than combating them one by one, which is the conventional approach in a current disease-based pharmacological paradigm.

This book contains the work of the world’s leading researchers in the field, including sections on the conceptual and methodological background of anti-aging pharmacology, the basic classes of anti-aging drugs, phytochemicals, outcomes of anti-aging developments and future directions. This book will be of interest to a wide audience, ranging from pharmacologists, medicinal chemists and academic researchers in gerontology, biomedical sciences and those in medical practice.

Cover image
Title page
Table of Contents
Copyright
Dedication
Contributors
Preface
Acknowledgments
Chapter 1. Geroscience—the concept
1. Introduction
2. Geroscience and anti-aging medicine
3. Anti-aging pharmacology: state of the art, unresolved issues, and perspectives
4. Human health span extension: the longevity dividend
5. Could aging be a treatable medical condition?
6. Concluding remarks
Chapter 2. Basic pathways and targets for anti-aging intervention
1. Introduction
2. Molecular and cellular mechanisms of aging
3. Overview of RNA quality control in aging
4. Conclusions and future perspectives
Chapter 3. Omics approaches in aging research
1. Introduction
2. Life expectancy clocks based on frailty indices
3. Epigenomics
4. Transcriptomics
5. Proteomics
6. Metabolomics
7. Ionomics
8. Cellular senescence
9. Gut microbiome
10. Conclusions and future perspectives
Chapter 4. Metformin
1. Introduction
2. Metformin and health
3. Metformin and longevity
4. Cause for caution
5. Mechanisms of action
6. Conclusion
Chapter 5. Rapamycin and rapalogs
1. Inhibition of mTOR signaling extends life span and promotes health span
2. The risks of rapamycin
3. Why does rapamycin have side effects?
4. A simple model: inhibition of mTORC1 is beneficial, inhibition of mTORC2 is detrimental
5. Specific targeting of mTORC1 signaling to promote healthy aging
6. Conclusion
Chapter 6. Anti-aging effects of phenolic compounds
1. Introduction
2. Alzheimer's disease
3. Other age-related diseases
4. Skin aging
5. Conclusions
Chapter 7. Curcumin
1. Introduction
2. Phytochemicalsas anti-aging therapeutics: mechanistic considerations
3. Curcumin: from chemical structure to therapeutic efficacy
4. Curcumin in aging-associated pathology prevention
5. Conclusions
Chapter 8. Pharmacology of NAD+boosters
1. Introduction
2. Overview of nicotinamide adenine dinucleotide biosynthesis pathways
3. Beneficial effects of nicotinamide adenine dinucleotide precursors in disease
4. Pharmacokinetics of nicotinamide adenine dinucleotideprecursors
5. Conclusions and future perspectives
Chapter 9. Mitochondrial modulators
1. Introduction
2. Mitochondria and aging-related signaling pathways
3. Mitochondria, telomeres, and aging
4. Age-related changes in the mitochondrial genome
5. Age-related alteration of mitochondrial permeability
6. Mitochondrial dynamics in aging
7. Mitochondrial metabolism and caloric restriction
8. Mitochondrial metabolism and exercise
9. Mitochondria-modulating potential of prolongevity compounds
10. Conclusion
Chapter 10. Nonsteroidal anti-inflammatory drugs
1. Introduction
2. Nonsteroidal anti-inflammatory drugs and diseases
3. Risks of long-term use of aspirin and other nonsteroidal anti-inflammatory drugs
4. Conclusions and future directions
Chapter 11. Senolytics in diseases: killing to survive
1. Discovery of cellular senescence
2. Senescence in cancer
3. Senescence in cardiovascular disease
4. Senolytics in metabolic disease
5. Senolytics in liver disease
6. Senolytics in kidney disease
7. Senolytics in lung disease
8. Senolytics in neurodegenerative disease
9. Senolytics in bone disease
10. Senolytics in skin disease
11. Conclusion
Chapter 12. Anti-aging skincare: the natural and organic way
1. Introduction
2. Current global trends
3. The effects of skin aging
4. Changes in connective tissues and skin surface pH in aging skin
5. Intrinsic and extrinsic aging factors
6. Natural and organic skincare
7. Natural anti-aging ingredients groups
8. Conclusion
Chapter 13. Protein kinase modulation for anti-aging intervention
1. Introduction
2. Janus kinase/signal-transducing adapter model signaling pathway
3. P70 ribosomal protein S6 kinase
4. Hippo signaling pathway
5. Mitogen-activated protein kinase signaling pathway
6. Conclusions and future perspectives
Chapter 14. The anti-aging mechanism of Berberine associated with metabolic control
1. Introduction
2. Mechanisms of berberine in targeting biological metabolic signaling
3. The clinical efficacy and side effects of berberine in age-related disease
4. Conclusions and future perspectives
Chapter 15. Growth hormone
1. Introduction
2. Growth hormone
3. Impact of aging on the somatotropic axis
4. Physiological meaning of age-related changes in hormone levels
5. Effects of growth hormone (GH) administration in GH-deficient vs endocrinolgocially normal adults
6. Treatment with growth hormone may affect epigenetic age
7. Conclusions
Chapter 16. Antioxidant pharmacology
1. Introduction
2. Free-radical hypothesis of aging: prelude
3. Free-radical malfunctions in oxidative metabolism
4. Free-radical redox-timer of aging in terms of system reliability theory
5. Antioxidant therapy: chemical background and experimental findings
6. Antioxidant therapy in light of system reliability theory
Afterword: conclusions and outlook
Index

Purchase options

Save 50% on book bundles

Institutional subscription on ScienceDirect

Vitaly Koltover